Concord Drugs Limited

CONCORD6

INE858L01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:54 31/05/2024 BST			5-day change	1st Jan Change
37.03 ^INR	-2.37%		-5.92%	-37.99%

03-19	Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer	CI
02-13	Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Concord Drugs Limited Approves Appointment of S. Koni Reddy as Whole Time Director

September 08, 2021 at 12:13 pm

Concord Drugs Limited at its board meeting held on September 08, 2021 approved the appointment of Mr. S. Koni Reddy as Whole Time Director with effect from September 08, 2021.

Latest news about Concord Drugs Limited

Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer	03-19	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Concord Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Concord Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/05/23	CI
Concord Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/05/23	CI
Concord Drugs Eyes INR 207 Million Rights Issue	14/04/23	MT
Concord Drugs Limited Announces Resignation of AnkurBisht, Company Secretary and Compliance Officer	08/04/23	CI
Concord Drugs Limited acquired 100% stake in Proton Remedies Private Limited for INR 14.2 million.	22/03/23	CI
Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023	14/02/23	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Concord Drugs Limited Announces Resignation of Rakshit Sethiya as Company Secretary and Compliance Officer	11/11/22	CI
Concord Drugs Limited announced that it has received INR 10.364063 million in funding	06/11/22	CI
Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer	04/11/22	CI
Concord Drugs Limited announced that it expects to receive INR 10.364063 million in funding	06/09/22	CI
Concord Drugs Limited agreed to acquire 100% stake in Proton Remedies Private Limited.	06/09/22	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/08/22	CI
Concord Drugs Limited Announces Director Changes	02/06/22	CI
Concord Drugs Limited Announces Resignation of Jyoti Goyal as Company Secretary and Compliance Officer	06/05/22	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Concord Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	18/10/21	CI
Concord Drugs Limited Approves Appointment of S. Koni Reddy as Whole Time Director	08/09/21	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	13/08/21	CI
Concord Drugs Limited Approves Resignation of T. Narsihma Reddy as Managing Director	13/08/21	CI

Concord Drugs Limited is an India-based pharmaceutical company. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup and suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellet system (MUPS). Its injectables include Amikacin Injection, Aceclofenac Injection, Artemether Injection, Adenosine Injection, and others. Iso Amyl 2-Cyano Acrylate is a tissue bio-adhesive. Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, and others.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CONCORD DRUGS LIMITED	-37.99%	4.44M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B